ClinicaliQ Trial Snapshot
- A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission — Recruiting • Phase II • Gastroenterology • NCT07156175.
- A trial testing whether SAR444336 maintains remission in microscopic colitis patients already on budesonide treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a parallel, placebo-controlled, multicenter, randomized, double-blind, Phase 2, proof of concept study. The study aims to evaluate the efficacy and safety of SAR444336 in adult participants with microscopic colitis. Participants are required to have a histologically confirmed diagnosis of microscopic colitis, be in clinical remission and be receiving budesonide therapy. The overall study duration is approximately 32 weeks. Conditions: Microscopic Colitis Interventions: SAR444336, Placebo Lead Sponsor: Sanofi Planned Enrollment: 54 participants